Take­da grabs Ari­ad, ex­pands on­col­o­gy port­fo­lio in $5.2B buy­out

Christophe We­ber, Take­da

Take­da has tak­en the next step in its glob­al re­struc­tur­ing, bag­ging Ari­ad Phar­ma­ceu­ti­cals for $5.2 bil­lion and pay­ing a whop­ping 74% pre­mi­um for its stock.

The deal gives Japan’s Take­da a big­ger can­cer drug port­fo­lio, with an al­ready ap­proved Iclusig on the mar­ket and a loom­ing de­ci­sion on briga­tinib, which Take­da be­lieves has block­buster po­ten­tial.

Ari­ad has been mak­ing progress since long­time CEO Har­vey Berg­er was forced out in the spring of 2015, a move trig­gered by a brew­ing share­hold­er re­volt that broke out af­ter Iclusig was briefly jerked out of the mar­ket and then al­lowed back on with a more lim­it­ed reach. The com­pa­ny fin­ished its rolling sub­mis­sion for briga­tinib last sum­mer, look­ing to get an OK to sell the ALK in­hibitor to pa­tients who no longer re­spond to Pfiz­er’s Xalko­ri.

In ear­ly De­cem­ber Ari­ad, now run by CEO Paris Panayiotopou­los, re­port­ed a me­di­an fol­low-up of 11-months, demon­strat­ed a pro­gres­sion-free sur­vival rate of 15.6 months with a 55% con­firmed ob­jec­tive re­sponse rate for non-small cell lung can­cer pa­tients tak­ing the 180 mg dose briga­tinib.

For Take­da, the buy­out marks an­oth­er step for­ward as it slash­es its R&D or­ga­ni­za­tion and re­groups in the US and Japan, great­ly re­duc­ing its pres­ence in the UK. The deal al­so marks the high val­u­a­tions tied to mar­ket­ed and late-stage drugs. Their fore­cast of $1 bil­lion-plus sales for briga­tinib, though, are sig­nif­i­cant­ly more ag­gres­sive than most an­a­lysts, who have been pre­dict­ing $500 mil­lion to $800 mil­lion in sales.

Christophe We­ber, pres­i­dent and chief ex­ec­u­tive of­fi­cer of Take­da, had this to say:

“This is a very ex­cit­ing time for Take­da as we will broad­en our hema­tol­ogy port­fo­lio and trans­form our glob­al sol­id tu­mor fran­chise through the ad­di­tion of two in­no­v­a­tive tar­get­ed ther­a­pies. Op­por­tu­ni­ties to ac­quire such high-qual­i­ty, com­ple­men­tary tar­get­ed ther­a­pies do not come of­ten, and we are very ex­cit­ed about the po­ten­tial for this trans­ac­tion to ben­e­fit pa­tients, our share­hold­ers and oth­er stake­hold­ers.”

2019 Trin­i­ty Drug In­dex Eval­u­ates Ac­tu­al Com­mer­cial Per­for­mance of Nov­el Drugs Ap­proved in 2016

Fewer Approvals, but Neurology Rivals Oncology and Sees Major Innovations

This report, the fourth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. It provides a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2016, scoring each on its commercial performance, therapeutic value, and R&D investment (Table 1: Drug ranking – Ratings on a 1-5 scale).

How to cap­i­talise on a lean launch

For start-up biotechnology companies and resource stretched pharmaceutical organisations, launching a novel product can be challenging. Lean teams can make setting a launch strategy and achieving your commercial goals seem like a colossal undertaking, but can these barriers be transformed into opportunities that work to your brand’s advantage?
We spoke to Managing Consultant Frances Hendry to find out how Blue Latitude Health partnered with a fledgling subsidiary of a pharmaceutical organisation to launch an innovative product in a
complex market.
What does the launch environment look like for this product?
FH: We started working on the product at Phase II and now we’re going into Phase III trials. There is a significant unmet need in this disease area, and everyone is excited about the launch. However, the organisation is still evolving and the team is quite small – naturally this causes a little turbulence.

Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

Just weeks after Merck’s star checkpoint inhibitor Keytruda secured FDA approval for a subset of bladder cancer patients, Swiss competitor Roche’s Tecentriq has failed in a pivotal bladder cancer study.

The 809-patient trial — IMvigor010 — tested the PD-L1 drug in patients with muscle-invasive urothelial cancer (MIUC) who had undergone surgery, and were at high risk for recurrence.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,400+ biopharma pros reading Endpoints daily — and it's free.

Ku­ra co-founder heads to Asian mul­ti-na­tion­al as biotech eyes the goal posts for lead drug

Six years after Kura Oncology snagged a farnesyl transferase inhibitor from J&J and leapt straight into clinical development, one of the biotech’s founders is leaving to start a new chapter in his career.

CMO and development chief Antonio Gualberto is exiting the company, and Kura — led by longtime biotech entrepreneur Troy Wilson — is on the hunt for a replacement. Wilson credited the CMO for some key biomarker work, including the discovery of the CXCL12 pathway as a target of their lead drug tipifarnib. Those biomarkers are being relied on to define the patient population most likely to benefit from the drug.

FDA waves Epizyme's $186K rare can­cer drug through to mar­ket — now get ready for the sec­ond act

After winning the hearts of the expert panel convened by the FDA despite a bleak in-house review and a checkered development history, Robert Bazemore has steered Epizyme to its first-ever OK for a rare cancer drug.

The approval in epithelioid sarcoma sets tazemetostat, now Tazverik, up nicely for a quick expansion to follicular lymphoma — a much bigger indication for which the biotech has just submitted an NDA.

UP­DAT­ED: Eli Lil­ly’s $1.6B can­cer drug failed to spark even the slight­est pos­i­tive gain for pa­tients in its 1st PhI­II

Eli Lilly had high hopes for its pegylated IL-10 drug pegilodecakin when it bought Armo last year for $1.6 billion in cash. But after reporting a few months ago that it had failed a Phase III in pancreatic cancer, without the data, its likely value has plunged. And now we’re getting some exact data that underscore just how little positive effect it had.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,400+ biopharma pros reading Endpoints daily — and it's free.

2019 a 'trans­for­ma­tive year' for phar­ma M&A. Is that a good thing?

Big Pharma keeps getting bigger.

Fueled by the mega-mergers between Bristol-Myers Squibb and Celgene and between Allergan and AbbVie, the industry last year saw $350 billion worth of M&A, according to the new year-end report from the consultants at PwC.  That’s a more than 50% increase on 2018.

“I kind of look at 2019 as a transformational year,” report author Glen Hunzinger told Endpoints News. 

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,400+ biopharma pros reading Endpoints daily — and it's free.

Drug-drug in­ter­ac­tions: FDA is­sues guid­ance on clin­i­cal, in vit­ro stud­ies

The FDA on Thursday finalized two guidances providing recommendations to drugmakers on evaluating potential drug-drug interactions (DDIs) for new drugs through clinical and in vitro testing.

“Together, the two final guidances describe a systematic risk-based approach to evaluation and communication of DDIs,” the FDA writes.

The two guidances finalize draft versions released in 2017 and have been revised to clarify their scope, provide additional considerations for conducting prospective studies and to explain “when DDI studies are needed for drugs identified as transporter substrates from in vitro studies.” Both guidances have been renamed from their draft versions to reflect an emphasis on investigating the cytochrome P450 (CYP) enzyme and transporter-mediated drug interactions.

Stephen Hahn, AP

The FDA has de­val­ued the gold stan­dard on R&D. And that threat­ens every­one in drug de­vel­op­ment

Bioregnum Opinion Column by John Carroll

A few weeks ago, when Stephen Hahn was being lightly queried by Senators in his confirmation hearing as the new commissioner of the FDA, he made the usual vow to maintain the gold standard in drug development.

Neatly summarized, that standard requires the agency to sign off on clinical data — usually from two, well-controlled human studies — that prove a drug’s benefit outweighs any risks.

Over the last few years, biopharma has enjoyed an unprecedented loosening over just what it takes to clear that bar. Regulators are more willing to drop the second trial requirement ahead of an accelerated approval — particularly if they have an unmet medical need where patients are clamoring for a therapy.

That confirmatory trial the FDA demands can wait a few years. And most everyone in biopharma would tell you that’s the right thing for patients. They know its a tonic for everyone in the industry faced with pushing a drug through clinical development. And it’s helped inspire a global biotech boom.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,400+ biopharma pros reading Endpoints daily — and it's free.